Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

NCT05860530 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05860530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05860530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
May 10, 2021
Completion date
September 8, 2021
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms